相关实验视频
Updated: May 14, 2025

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.5K
在血糖控制中人工智能驱动干预的有效性:随机对照试验的系统审查和元分析
Khadija Elmotia1, Oumaima Abouyaala1, Soukaina Bougrine1
1Laboratory of Biology and Health, Department of Biology, Faculty of Science, Ibn Tofail University, BP 133, Kenitra, Morocco.
Primary care diabetes
|May 12, 2025
概括
人工智能 (AI) 决策支持系统显著改善糖尿病患者的血糖控制,增加时间范围 (TIR) 和降低HbA1c. 需要进一步的研究来个性化人工智能方法以获得最佳结果.
科学领域:
- 医疗信息学 医疗信息学
- 医疗保健中的人工智能
- 糖尿病管理 糖尿病管理
背景情况:
- 糖尿病影响全球数百万人,需要先进的管理策略.
- 通过时间范围 (TIR) 和HbA1c测量的血糖控制,对于预防糖尿病并发症至关重要.
- 人工智能驱动的决策支持系统 (AI-DSS) 为个性化和改进的糖尿病护理提供了潜力.
研究的目的:
- 系统地审查和分析AI-DSS在改善糖尿病患者的血糖控制 (TIR和HbA1c) 的有效性.
- 评估人工智能干预对基于随机对照试验 (RCT) 的关键血糖控制指标的影响.
主要方法:
- 17个RCT的系统审查和随机效应元分析.
- 包括到2024年12月发表的研究,重点关注用于糖尿病管理的AI干预措施.
- 使用Cochrane偏差风险工具进行偏差风险评估.
主要成果:
- 人工智能干预显著改善了范围内的时间 (TIR),平均差异为0.54 (95% CI:0.05-1.03).
- 人工智能干预显著降低了HbA1c水平,标准化平均差异为-0.91 (95% CI: -1.23至-0.58).
- 发现了高异质性 (I2 > 90%) 和潜在的出版偏差,建议谨慎解释.
结论:
- 人工智能驱动的决策支持系统在增强糖尿病患者的血糖控制方面具有显著的潜力.
- 效果的变化凸显了基于人工智能的个性化糖尿病管理策略的需要.
- 进一步进行高质量的研究是有必要的,以解决异质性,并确认发现.
相关概念视频
Diabetes: Management and Pharmacotherapy
213
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
213
Oral Hypoglycemic Agents: Biguanides and Glitazones
141
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
141
Dipeptidyl Peptidase 4 Inhibitors
136
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
136
Diabetes Mellitus: Overview and Type I Subtype
2.3K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.3K
Glucagon-like Receptor Agonists
270
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
270
Diabetes Mellitus: Type 2 and Gestational
2.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K

